Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 68 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases September 14, 2021 First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... December 4, 2023 Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial,... July 11, 2023 Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... May 25, 2022 Load more HOT NEWS Beloved Preschool Teacher Dies of Breast Cancer, Leaving Behind 9-Year-Old Son Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows Cancer in My Community: How People With Cancer Access Care in... Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in...
